Aulis Capital
Status
ACTIVE
Global HQ
Kowloon Bay, Hong Kong
Countries of investment
- United States
- China
Investment stages
- Seed
- Series A
- Series B
- Growth
Industries
- Biotechnology
- Life Sciences
- Biologics
- Pharma
- MedTech
- Medical Devices
- Diagnostics
- Digital Health
- Health Tech
About
Aulis Capital is a Hong Kong-based healthcare investment firm, also operating from California, founded in 2025 by Nisa Leung after 19 years as a managing partner at Qiming Venture Partners. In November 2026 it announced the final close of its debut fund, Aulis Capital Fund I, L.P., with $200M of total commitments to invest in early and growth stage life sciences and healthcare companies across the East and West. Former McKinsey senior partner Franck Le Deu joined in 2026 as a venture partner to build its life sciences practice in China and Asia, alongside venture partners Lingshi Tan, Paul Li, Alwin Poon and Ethan Than. Its early investments include EpiBiologics, a San Mateo protein degradation company in whose $107M Series B, co-led by GV and Johnson & Johnson Innovation, Aulis participated in January 2026.
Aulis Capital is a Hong Kong-based healthcare investment firm, also operating from California, founded in 2025 by Nisa Leung after 19 years as a managing partner at Qiming Venture Partners. In November 2026 it announced the final close of its debut fund, Aulis Capital Fund I, L.P., with $200M of total commitments to invest in early and growth stage life sciences and healthcare companies across the East and West. Former McKinsey senior partner Franck Le Deu joined in 2026 as a venture partner to build its life sciences practice in China and Asia, alongside venture partners Lingshi Tan, Paul Li, Alwin Poon and Ethan Than. Its early investments include EpiBiologics, a San Mateo protein degradation company in whose $107M Series B, co-led by GV and Johnson & Johnson Innovation, Aulis participated in January 2026.
Investment Thesis
Aulis Capital is a global healthcare investor backing early and growth stage companies in biotech, medical technology, medical devices, diagnostics and digital health. It partners with entrepreneurs building cross-border businesses that bridge Western and Asian life sciences, using China's scale, engineering and clinical development strengths to help companies reach global markets. Its edge is founder Nisa Leung's two decades building one of China's leading healthcare venture practices and a proprietary network of hospitals, academic institutions and healthcare companies in Asia and globally.
Manager's Experience
Nisa Leung joined Qiming Venture Partners in 2006, launched and led its healthcare practice as managing partner for 19 years until her departure in February 2025, overseeing about 220 startups with some 300 drug assets including Gan & Lee Pharmaceuticals, Zai Lab, CanSino Biologics and Insilico; earlier she co-founded Biomedic Holdings, whose Novamed and U-Systems were acquired by SciClone and GE Healthcare. Venture partner Franck Le Deu is a McKinsey senior partner emeritus who led its Greater China healthcare practice and co-led its Asia healthcare practice before founding KerZheng Ventures in 2025. Venture partner Lingshi Tan is executive chairman and former CEO of Caidya, founder of dMed Clinical, spent about 20 years at Pfizer and chaired the DIA Global Board.
Team
Nisa Leung - Founding Managing Partner
Mingyu Xue - Principal
Grace Ng - Chief Financial Officer
Franck Le Deu - Venture Partner
Lingshi Tan - Venture Partner
Paul Li - Venture Partner
Alwin Poon - Venture Partner
Ethan Than - Venture Partner
Portfolio
EpiBiologics
Shyld AI